News

2021-08-20
Latest News
On July 18, 2021, West China Hospital of Sichuan University (“WCHSCU”), put into operation at its heartland a translational medicine (TM) complex as TM research infrastructure and a key clinical research facility of provincial and national importance. On the ceremony
Read More
2021-02-25
Latest News
On ​February 25, Westvac had an industrial and commercial change, adding Shanghai Pharmaceutical(601607.SH), Chengdu Yike Investment Management Co., Ltd. and other shareholders. At the same time, the company’s registered capital increased from 10 million yuan to 790 million yuan, an increase of 7800%, according to the data from Tianyancha APP.
Read More
2020-11-25
Latest News
On November 25, the signing ceremony of the cooperation agreement between Chengdu High-Tech Industrial Development Zone, Shanghai Pharmaceutical and Westvac Biopharma(here in after referred to as “Westvac”) was held in Shanghai. The total investment of this cooperation exceeded 5.1 billion yuan.
Read More

About Us

WestVac Biopharma is founded by Academician Wei Yuquan from West China Hospital of Sichuan University, together with 10 scientists from State Key Laboratory of Biotherapy(SKLB). Its headquarter is located in the International Bio-Town, Chengdu. The CEO of WestVac Biopharma is Prof.Wei Yuquan, who is the Academician of Chinese Academy of Sciences as well as the Director of State Key Laboratory of Biotherapy.

WestVac is committed to exploring the latest biotherapy technologies for major diseases, including infectious diseases, malignant tumors, cardiovascular diseases, and so on. It has attached great importance in the Research and Development(R&D) of COVID-19 vaccine especially and building a COVID-19 vaccine production platform. State Key Laboratory of Biotherapy (SKLB) was established by the Ministry of Sciences and Technology of China in 2005 and became one of the National R&D Platforms for Novel Drugs founded by the Ministries of Sciences and Technology as well as that of Health of China in 2008. It is also supported by National Collaborative Innovation Program and has become the National Collaborative Innovation Center for Biotherapy since 2013.

West China Hospital of Sichuan University,founded in 1892, is the National Center for Diagnosis and Treatment of Severe and Critical Diseases in Western China. It is also the world’s largest comprehensive hospital complex located in one campus area.

Relying on the medical resources of State Key Laboratory of Biotherapy and West China Medical Center, WestVac has adopted recombinant protein methodology to develop the COVID-19 vaccine. Because of the safety of the protein vaccine , it is also the only COVID-19 vaccine approved for the use in children over 3 years old in China.

The vaccine was approved by the National Medical Products Administration for clinical trials on August 21,2020. Phase I/II clinical trials have been completed, and phase III clinical trials are being carried out in Nepal, Kenya, Japan and other countries.The vaccine targets the spike protein binding domain (S-RBD) of SARS-CoV-2, producing neutralizing antibodies to block COVID-19 infection of human cells. The result was published on Nature, the world’s famous scientific journal on July 29th, 2020. It has also been the first paper of COVID vaccine published by Nature since the pandemic outbreak. The S-RBD gene of the COVID-19 virus is introduced into the insect cells, which were used as a factory to produce high-quality recombinant vaccine protein and then does refined purification. Such technology is easy to be mass-produced and brought to the market.

WestVac Biopharma is committed to becoming the world`s leading vaccine and immunotherapy platform.

Read More

Product

Phase I and II clinical studies of the recombinant COVID-19 vaccine (Sf9 cells) of West China Hospital of Sichuan University have been completed. WestVac has joint hands with Sichuan Development Holding Co., Ltd. and Shanghai Pharmaceuticals Holding Co., Ltd. in terms of COVID 19 vaccine R&D and the construction of the “Tianfu Vaccine Valley”. It has signed the investment contract with Sichuan Development Holding Co., Ltd. and Shanghai Pharmaceuticals Holding Co., Ltd. for the vaccine R&D, securing a Series A funding of nearly 300 million yuan on November 16th. And It has then signed the contract with Chengdu High-tech Zone and Shanghai Pharmaceuticals Pharmaceuticals Holding Co., Ltd. to jointly build a full-chain vaccine industry and build the "Tianfu Vaccine Valley" on Novemeber 25th

Industrialization

The core equipment is home-grown in China. With the production capacity enlarged, the annual output of the vaccines can reach hundreds of millions of bottles. In addition, a large-scale plant for GMP vaccine production is being built, streamlined production line being designed, and production processes being optimized, employing the power of industrialization in the massive production of vaccines with good quality and quantity.

overview
overview
overview